| Literature DB >> 19772855 |
Huiguo Lai1, Minghao Feng, Virginia Roxas-Duncan, Sivanesan Dakshanamurthy, Leonard A Smith, David C H Yang.
Abstract
Quinolinol derivatives were found to be effective inhibitors of botulinum neurotoxin serotype A (BoNT/A). Studies of the inhibition and binding of 7-(phenyl(8-quinolinylamino)methyl)-8-quinolinol (QAQ) to the light chain domain (BoNT/A LC) showed that QAQ is a non-competitive inhibitor for the zinc protease activity. Binding and molecular modeling studies reveal that QAQ binds to a hydrophobic pocket near the active site. Its inhibitor effect does not involve the removal of zinc ion from the light chain. A 24-mer SNAP-25 peptide containing E183 to G206 with Q197C mutation (Peptide C) binds to BoNT/A LC with an unusually slow second order binding rate constant of 76.7M(-1)s(-1). QAQ binds to Zn(2+)-free BoNT/A LC with a K(D) of 0.67microM and to Peptide C-BoNT/A LC complex with a K(D) of 2.33microM. The insights of the interactions of quinolinols and peptides with the zinc protease of BoNT/A should aid in the development of inhibitors of metalloproteases.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19772855 DOI: 10.1016/j.abb.2009.09.008
Source DB: PubMed Journal: Arch Biochem Biophys ISSN: 0003-9861 Impact factor: 4.013